UN Sustainable Development Goals

Our Action: More than 71 million people around the world used Lilly medicines in 2025. Through investments in people, medicines and health systems, we reached 40 million people in resource-limited settings in 2025, five years ahead of our 2030 goal of reaching 30 million people. Lilly tailors its approaches to patenting in Least Developed Countries, recognizing that each country may have unique challenges. This may include voluntary licensing, non-assert policies, or selective approaches to filing, alongside capacity-building initiatives that foster local innovation.

Enable, Reach, Community Engagement, Patient Safety, Employee Well-Being

Our Action: We work to improve educational opportunities for children living in underserved communities in Indianapolis. Lilly and the Lilly Foundation focus on early childhood education, supporting quality schools and STEM (science, technology, engineering and math) education.

Community Engagement

Our Action: We continue to build a dynamic and inclusive company by embedding inclusion into our leadership, systems and culture. It is core to our business success because it fosters innovation and allows us to connect more closely with our customers.

Inclusion, Employee Engagement, Human Rights

Our Action: Water is a critical resource that we are focused on using wisely. We continue to assess our water risks as we focus on conserving water, reducing our intake and improving water quality. We seek to have 100% of Lilly sites meet predicted no-effect concentrations (PNEC) for Pharmaceuticals in the Environment by 2030.

Water, Waste

Our Action: By 2030, we seek to source 100% of purchased electricity from renewable sources and to achieve carbon neutrality in our own operations (Scope 1 and 2 emissions). Additionally, we're enhancing the tracking and reporting of greenhouse gas emissions across our value chain.

Climate

Our Action: We maintain a safe workplace and provide opportunities for employees to learn and develop. We also believe that working with a varied set of suppliers helps us accelerate innovation and deliver strong results. In 2025, we spent about $1.7 billion with nearly 1,600 suppliers classified as small businesses as defined by the U.S. Small Business Administration’s (SBA) small business size standards.

Employee Safety, Employee Learning and Development, Supplier Development

Our action: We partner with industry peers and other organizations to improve global health, including through NCD care programs and support for community health workers in low- and middle-income countries. We also work with disaster relief organizations to provide medicines and help communities recover.

Access: React, Community Engagement

Our Action: We work to address complex health challenges around the world, including a focus on noncommunicable diseases and people living in resource-limited communities in the U.S. and low- and middle-income countries. We are focused on expanding equitable and affordable access to our breakthrough medicines so that they can reach more people. Additionally, we uphold pay equity for all employees in our workforce. We conduct pay equity studies on our workforce globally and believe that pay equity is critical to our success in supporting a global and inclusive workforce.

Access: Reach, Community Engagement, Employee Well-Being

Our Action: We work to reduce the environmental footprint of our operations, including optimizing fuel efficiency across our vehicle fleet and pursuing energy efficiency and renewable electricity at our facilities.

Climate

Our Action: We strive to embed environmental innovation early in the product development lifecycle through our focus on green chemistry and end-product engineering. By 2030, our goal is for 100% of plastic waste to be repurposed for beneficial use, with at least 90% recycled or reused, and to achieve zero waste to landfill from routine operations.

Waste, Product Stewardship,

Our Action: By 2030, we seek to source 100% of purchased electricity from renewable sources and to achieve carbon neutrality in our own operations (Scope 1 and 2 emissions). Additionally, we're enhancing the tracking and reporting of greenhouse gas emissions across our value chain.

Climate

Our Action: We have adopted rFC, a scientifically proven, sustainable alternative to the horseshoe crab-sourced testing reagent, LAL, in many areas of our testing operations. This is especially important given that several species of crabs are under threat or endangered from habitat loss and overharvesting.

Water, Product Stewardship, Biodiversity

Our Action: We strive to protect designated biodiversity rich areas, manage existing biodiversity at our sites and enhance biodiversity within the communities where we operate.

Biodiversity

Our Action: We train all of our employees in ethical business practices and have systems in place to detect violations of laws, regulations and company policies, including those related to anti-corruption. We also expect our suppliers to abide by Lilly’s human rights standards and our Supplier Code of Business Conduct.

Ethics and Compliance, Corporate Governance, HSE Governance, Supply Chain Management, Human Rights

Our Action: Lilly collaborates with many organizations, including the Eli Lilly and Company Foundation, to advance government priorities, strengthen local health care systems and improve access to care. Additionally, we collaborate with organizations to extend the reach of our impact on topics that affect our business and communities, with an emphasis on economic health and education.

Enable, Reach, Community Engagement